Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFOXIRI versus mFOLFOX6 for MRI-defined high-risk rectal cancer
ChiCTR2000032191Phase 2Recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- May 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, folinic acid, oxaliplatin and irinotecan in rectal adenocarcinoma (2 arms), sponsored by Yunnan Cancer Hospital. Primary endpoint: R0 resection rate. Started May 2020; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000032191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032191.